A Conoah e a Nochein Jianhua anunciaram conjuntamente a concessão de licenças autorizadas para a dupla resistência CD20xCD3 e Prolium.

A Kansheng and a joint announcement by Nuo Cheng Jianhua, and both companies and their joint venture jointly and Prolium Bioscience reached a licensing agreement to authorize Prolium to develop and commercialize CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the terms of the protocolo, Prolium will obtain the rights to develop, register, produce and commercialize ICP-B02 in the global non-oncology field and the oncology field outside Asia. Nuo Cheng Jianhua and Kansheng will receive a total payment of up to US$520 million, including initial payment and recent payment, as well as additional payments for achieving clinical development, registration and commercialization milestones, and both parties will receive a minority equity stake in Prolium. At the same time, Nuo Cheng Jianhua and Kansheng will also receive tiered royalty fees for the net sales of future products.